Health Care

Hot News: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

0 12

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) closed its last session at $129.42 with the change of +2.07%. The market capitalization of the company is $29.02B with an average Volume of 1.84 million shares. The stock currently has its 52-Week High range of $193.45 and 52-week low range of $110.56. The Price to Book (P/B) ratio stands at 3.47. The stock traded total quantity of 969.89 thousand shares.

Currently Alexion Pharmaceuticals, Inc. (ALXN) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “16″ Analysts”. “0” rated “Sell” for the company. “6” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.

Analysts are expecting that the company to achieve $175.42 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $221.00 however minimum price target advised by analysts is $132.00. The Median price target for the stock is measured at $180.00.

Presently, Analysts decided consensus EPS estimate of $1.19 for present quarter and one month ago projected EPS estimate was at $1.19. If we take a look at back 3 month ago, consensus EPS estimate was $1.32.

A current consensus EPS estimate for next quarter is at $1.29 and 3 month ago EPS forecast was $1.44. Have a look at back 1 month ago, consensus EPS forecast was seen at $1.29.

For current fiscal year, most recent EPS estimate is set at $4.66 based on Analyst consensus and three month ago consensus EPS opinions was at $5.06. During period one month ago, consensus EPS forecast was decided at $4.67.

A current consensus EPS projection for next fiscal year is observed at $5.98 and one month ago consensus EPS forecast was at $5.98. Take a look at back three month ago, consensus EPS estimate opinions was decided at $6.62 by analysts.

One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 16 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 6 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.

Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 14 said a “Buy Rating” and 0 announced “Overweight Rating”. 8 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

Advirtisement

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.

Newsletter